Table 2.
Travel History, Gastrointestinal Symptoms, and Treatment History in 168 Strongyloides Seropositive Patients
| Characteristics | SSp Patients, No. (%) |
|---|---|
| Travel history | |
| None | 20/79 (25) |
| Mexico, Central America, or the Caribbean | 47/79 (60) |
| Asia | 10/79 (13) |
| Other | 2/79 (3) |
| Gastrointestinal symptoms | 14/153 (9) |
| Abdominal pain | 2/153 (1) |
| Nausea | 1/153 (1) |
| Diarrhea | 10/153 (7) |
| Other | 1/153 (1) |
| Ivermectin treatment regimenb | |
| Once daily for 2 d | 67/92 (72) |
| Once weekly for 2 doses | 14/92 (15) |
| Other regimen | 6/92 (7) |
Abbreviation: SSp, Strongyloides-seropositive.
aData represent no./total (%) of patients; denominators (totals) vary according to availability of data.
bAll were treated with ivermectin, of whom 92 patients had documented treatment regimens.